variant of adalimumab (Biora Therapeutics)

N/A

Report date: 2026/01/04 10:21:38

Base Information

Drug Namevariant of adalimumab (Biora Therapeutics)
Drug Alias NameBT-002PGN-001BT-001PGN-OB1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsInflammation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBiora Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesClick Therapeutics IncBiora Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsInflammation
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A